The main objective of promoting this new clinical diagnostic technology service provider company in India is to directly promote to the end-user clinicians and patients (defined as “Customers” hence) with the advanced molecular diagnostic technologies and cytopathological services of clinical relevance in the area of women’s cancer and blood viruses testing being directly used in the routine patient management, care and decision to treat by surgical interventions.

Gentech Diagnostics, through its association with expert scientists on the global arena as well as leading the Indian clinical fraternity in women’s genital cancer have strived hard over a decade to bring about a subtle change to adopting the state-of-the-modern-care technologies over the conventional pathological technologies. Today, the entire gynaecologic oncology community in the Indian subcontinent looks upon Gentech as a lab with most contemporary “knowledge” in our chosen area of core competence. Working in the very close proximity with Indian experts, we have been able to formulate the first “Evidence-based clinical compilation” of various screening procedures for cervical cancer, which is referred by every practicing gynaecologist and gynaec- oncologist of India.

By bridging a link with end-users (customers) we ensure not only quality products at affordable prices but also conducive personalized services which are necessary in molecular diagnostics/ clinical research industry.

The NATIONAL CLINICAL REFERENCE LABORATORY, a laboratory unit of the Company is set up with the commissioning of Digene’s modern proprietary Hybrid Capture 2 system consisting of chemiluminescence based 96-well Plate Luminometer, Tube Luminometer, Rotary Shaker, Heating Block and automated micropipetting system. The facility launched in May 2001 performs tests on bi-weekly intervals. The Laboratory holds some of the world reputed Gynaecologists and Hepatologists in India on advisory and consulting panel, to substantiate our commitment to Indian diagnostic industry.

The Company also plans to create a networking of Referral Laboratories in the major cities in India through franchisee system involving financial participation from the leading pathological laboratories.

The current core area as a National Clinical Reference Laboratory being QIAGEN’s US FDA approved Hybrid Capture 2 HPV DNA test for early diagnosis, management and prevention of Cervical Cancer afflicting women in their most reproductive age group and constituting a major cause of death due to any cancers among women. Also the other clinical test procedures being marketed are the US FDA approved Liquid Based Cytology (LBC), Chlamydia DNA, Gonorrhoeae DNA technologies in the STD area as well as HPV Genotyping in the Cervical Precancer area and Cytomegalovirus DNA technology in immunocompromised and organ transplant area. The expanded core area pursued by the company is Hepatitis B, the product profile is represented by HBV DNA and HBV genotype on real time PCR technology in therapeutic monitoring of chronically infected liver patients. Soon, the molecular tests for HCV RNA quantitative and genotyping as well as HIV-1 RNA tests are scheduled for launch.

The Company pursues active interest in promoting MOLECULAR BIOLOGY DIAGNOSTICS and SPECIALTY IMMUNODIAGNOSTICS in the area of HIV/ AIDS, HEPATITIS, CANCER and AUTOIMMUNE Markers and other tropical diseases diagnostics such as MALARIA, TUBERCULOSIS, DENGUE, SALMONELLA etc. for immediate future expansion plans. Some of the major projects being followed by the Company are directed towards development of chimaeric HPV vaccine, development of Tuberculosis diagnostic assays, BCG Booster and setting up of the BioBanks in India.

The promoter of the Company, Dr Dinesh Gupta, is himself considered as an experts and an important resource centre in the cervical cancer and sexually transmittable infections. He is an executive (life) member of Indian Association for Cancer Research (IACR); a life member of Indian Menopause Society (IMS); Association of Gynaecologic Oncologists of India (AGOI); Indian Society for Colposcopy and Cervical Pathology (ISCCP) and Asia-Oceania Research Organization in Genital Infections and Neoplasia (AOGIN). He has been engaged in conducting CMEs all over India with other clinical experts from India and abroad.

 TYPES OF SERVICES:
Gentech’s commitment to the elite gynaecology and hepatology specialities in our core area of operation is to provide the quality of clinical tests at extremely competitive and affordable prices.
To reinforce our faith in direct-to-clinicians, the Company promotes a NATIONAL CLINICAL REFERENCE LABORATORY, to support our laboratory services in cohesion with top echelon pathology laboratories in India to commercially promote tests to the Indian Gynaecologists, Hepatologists and Oncologists at the very competitive prices making a modern technology in this “genomic era” more affordable to those who are less fortunate. This Laboratory is also designed to routinely train the laboratory technologists from India and neighbouring countries including Bangladesh and UAE. The Laboratory services also extend to running clinical trials for the therapeutic manufacturers to monitor the patients at the periodic intervals on the efficacy of the long-term therapeutic effects. We have already finished two clinical trials and a third, with a leading multinational is on for last two years.

 ORGANISATIONAL CULTURE:
The Company believes strongly in minimal but technically competent and committed manpower to deal with the class of our target markets. It is important that they carry out effectively the technology presentations, follow-up potentials and convert them into long-term outsourcing partners, provide technology training, concentrate trouble-shoot through individual attention and care within shortest possible time, support with most appropriate clinical interpretations of the technologies being marketed and finally gain “friendship access” to elite customers. With the benefits of Information Technology era, it is possible to be constantly in-touch with the large number customers simultaneously. This is how we see developing long-lasting relationship with them. Our marketing collaborating company provides a constant supplement of technical resource and support which is drafted, edited or summarized, if the need be, in the manner easily understood in our patients. We are largely acknowledged and appreciated in our novel endeavour in Indian clinical diagnostic industry.